Immunotherapy and Other Nontargeted Approaches for Lung Cancer | Proceedings from a live event held adjunct to the 2021 ASCO Annual Meeting

published 1 week ago by Dr Neil Love

Featuring perspectives from Drs Mark Awad, David R Spigel and Heather Wakelee, including the following topis: Immunotherapy in the (Neo)Adjuvant Setting Introduction (0:00) Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 — Sulfi Ibrahim, MD (1:39) Key relevant data sets (11:36) First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 (continued) — Dr Ibrahim (16:34) Case: A woman in her mid-60s with metastatic squamous cell carcinoma of the lung — PD-L1 75% — Margaret Deutsch, MD (22:42) Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung and brain metastases — PD-L1 90% — Joseph Martins, MD (25:44) Case: A man in his early 70s with recurrent metastatic adenocarcinoma of the lung — TP53 and KRAS G12A mutations — Raymond Lobins, DO (30:05) Case: A man in his mid-60s with metastatic adenocarcinoma of the lung and active hepatitis C — Maria Regina Flores, MD (35:31) Case: A man in his mid-70s with metastatic adenocarcinoma of the lung — PD-L1 1% — Dr Ibrahim (37:42) Current Treatment Paradigm for Small Cell Lung Cancer (SCLC) Case: A man in his late 50s with extensive-stage SCLC — Rohit Gosain, MD (47:41) Case: A woman in her mid-60s with limited-stage SCLC — Ranju Gupta, MD (55:33) CME information and select publications

more episodes from Research To Practice | Oncology Videos